Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers | Zendy

John P. O’Donnell | Zendy; K. W. Lawrence | Zendy; Karthick Vishwanathan | Zendy; Vinayak Hosagrahara | Zendy; John P. Mueller | Zendy

Open Access

Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers

Author(s) -

John P. O’Donnell,

K. W. Lawrence,

Karthick Vishwanathan,

Vinayak Hosagrahara,

John P. Mueller

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01808-18

Subject(s) - pharmacokinetics , antibiotics , pharmacology , excretion , medicine , metabolic clearance rate , metabolism , chemistry , biochemistry

Zoliflodacin is a novel spiropyrimidinetrione with activity against bacterial type II topoisomerases that inhibits DNA biosynthesis and results in accumulation of double-strand cleavages in bacteria. We report results from two phase 1 studies that investigated the safety, tolerability, and pharmacokinetics (PK) of zoliflodacin and absorption, distribution, metabolism, and excretion (ADME) after single doses in healthy volunteers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research